Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

1. Is the biology right?

• Somatic driver evidence: no · None of TOP2A, TOP2B has somatic-mutation evidence in childhood acute lymphoblastic leukemia

  Rule: Open Targets has somatic-mutation evidence for the target in this cancer. Source: Open Targets: TOP2A in childhood acute lymphoblastic leukemia, 2026-11-11
• Human genetic evidence: no · No germline or somatic evidence for TOP2A, TOP2B in childhood acute lymphoblastic leukemia

  Rule: Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence. Source: Open Targets: TOP2A in childhood acute lymphoblastic leukemia, 2026-11-11
• Pediatric target: no · Not on the FDA list

  Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study. Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
• Haematologic cancer: yes · Haematologic

  Rule: From the indication, or the registry conditions when no indication matches. Source: ClinicalTrials.gov NCT01949129, 2026-11-11

  Published context: Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid (BIO / Informa / QLS 2021, 2011–2020). Population-level, not a prediction.

• Background therapy: Fludarabine, Cyclophosphamide: standard agents, not counted in these flags.
• TOP2A (via VP16): Open Targets has no association between TOP2A and childhood acute lymphoblastic leukemia. · Open Targets: TOP2A in childhood acute lymphoblastic leukemia
• TOP2B (via VP16): Open Targets has no association between TOP2B and childhood acute lymphoblastic leukemia. · Open Targets: TOP2B in childhood acute lymphoblastic leukemia

• Not loaded on this app yet: Normal-tissue expression in vital organs. Source: Human Protein Atlas (ticket 36).
• Not loaded on this app yet: Pan-essential in cell lines. Source: DepMap (ticket 36).
• Not loaded on this app yet: Approved drug on this target. Source: Drugs@FDA (ticket 30).

2. Can the result be trusted?

• Randomised: no · Non-randomised

  Rule: Registry allocation field. Source: ClinicalTrials.gov NCT01949129, 2026-11-11
• Small denominator: no · 1800 planned; each patient moves a rate by 100 ÷ 1800 = 0.1 points

  Rule: Enrolment under 30; the arithmetic is shown, not a benchmark. Source: ClinicalTrials.gov NCT01949129, 2026-11-11
• Primary endpoint is overall survival: yes · Overall Survival (OS) Stratum 1a (randomisation TBI+ chemo-conditioning vs. chemo-conditioning only); Event free survival (EFS) Stratum 2 (mismatched donor transplantation); Overall Survival (OS), Stratum 1b: MSD/MD without randomisation

  Rule: A registered primary outcome measure names overall survival. Source: ClinicalTrials.gov NCT01949129, 2026-11-11
• Results overdue: no · Primary completion expected 2030-06-01; not yet due

  Rule: Primary completion (actual) more than 12 months ago and no results posted to the registry. Source: ClinicalTrials.gov NCT01949129, 2026-11-11

• Not loaded on this app yet: Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff. Source: Readout extraction (ticket 32).
• Not loaded on this app yet: Primary endpoint changed between registry versions. Source: Registry versions in the store (ticket 32).

3. What must it beat?

• Not loaded on this app yet: Control-arm result and approved therapies for the same segment, with label links. Source: Drugs@FDA, FDA labels and readouts (tickets 30, 32).

4. Too crowded, or too late?

• Stopped on this target: 728 terminated, withdrawn or suspended trials of drugs against TOP2A; 3 of the 200 most recent give no reason. Reasons are quoted as the registry gives them on the target page. · TOP2A: what already stopped

• Not loaded on this app yet: Programs on the target by phase and months behind the leader. Source: Programs and Drugs@FDA (ticket 33).

5. Can it be approved, and stay approved?

• Single-country: no · 119 sites in 31 countries; 0 in the United States (0%)

  Rule: All listed sites are in one country; the share of US sites is shown. Source: ClinicalTrials.gov NCT01949129, 2026-11-11
• EU paediatric investigation plan: yes · EMEA-000883-PIP01-10-M05 (treosulfan, Conditioning treatment prior to haematopoietic-progenitor-cell transplantation): PM: decision on the application for modification of an agreed PIP, 9 Sept 2020; compliance positive 25 Mar 2022

  Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-000883-PIP01-10-M05, 2026-11-11
• EU orphan designation: yes · EU/3/04/186 positive 22 Feb 2004: Conditioning treatment prior to haematopoietic-progenitor-cell transplantation; EU/3/06/424 withdrawn 29 Jan 2007: Conditioning treatment prior to haematopoietic-progenitor-cell transplantation; EU/3/00/011 expired 30 Dec 2000: Conditioning treatment prior to haematopoietic-progenitor-cell transplantation

  Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
• Authorised in the EU: yes · Thiotepa Riemser: authorised since 26 Mar 2021; Tepadina: authorised since 15 Mar 2010; Trecondi: authorised since 20 Jun 2019; Busulfan Fresenius Kabi: authorised since 22 Sept 2014; +1 more

  Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
• FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link

  Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
• FDA pediatric oncology approval: yes · Treosulfan [Grafapex], 21 Jan 2025: In combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with myelodysplastic syndrome (MDS); Treosulfan [Grafapex], 21 Jan 2025: In combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia (AML); Busulfan [Busulfex], 13 Jan 2003: For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia

  Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
• Registered studies open to children: yes · 1226 interventional studies of VP16, Thiotepa, Treosulfan, Busulfan include patients under 18; 250 are recruiting, not yet recruiting or active

  Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11

• Caveat: Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality.
• Rare pediatric disease voucher: FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. · FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

• Not loaded on this app yet: Precedent approvals for target, modality and endpoint; accelerated-approval status. Source: Drugs@FDA and FDA accelerated-approval tables (ticket 30).

6. Can the sponsor finish?

• Sponsor: St. Anna Kinderkrebsforschung (academic or other) · ClinicalTrials.gov NCT01949129
• study chair: Christina Peters, Prof. MD PhD, St. Anna Kinderspital, Vienna, Austria · Person page
• study chair: Peter Bader, Prof. MD PhD, Goethe University · Person page
• study chair: Franco Locatelli, Prof. MD PhD, Ospedale Pediatrico Bambino Gesù, Rome, Italy · Person page
• study chair: Anita Lawitschka, Assoc. Prof. MD, St. Anna Kinderspital, Vienna, Austria · Person page

• Not loaded on this app yet: Filed cash, quarterly spend and the runway arithmetic. Source: SEC XBRL company facts (ticket 37).
• Not loaded on this app yet: Sponsor's completed vs stopped oncology trials and results-reporting record. Source: Registry, by company (ticket 37).

What public data cannot tell you

Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.